Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early testosterone gel in critically ill patients
2019-004599-20Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Critical illness polyneuromyopathy (CIPNM), acute quadriplegic myopathy (CIM) and Critical Illness Polyneuropathy (CIP) comparing Testosterone gel with Placebo gel (2 arms). Primary endpoint: 6-minute walk distance at 3 months. Started May 2021; status: active.
02
Drugs
testosterone
03
Conditions
Critical illness polyneuromyopathy (CIPNM)acute quadriplegic myopathy (CIM)Critical Illness Polyneuropathy (CIP)
Beyond the preview
Go deeper on 2019-004599-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004599-20.